212 related articles for article (PubMed ID: 31515933)
1. Dose down-titration of biological disease-modifying antirheumatic drugs in daily clinical practice: Shared decision-making and patient treatment preferences in Japanese patients with rheumatoid arthritis.
Komiya T; Takase-Minegishi K; Sakurai N; Nagai H; Hamada N; Soejima Y; Sugiyama Y; Tsuchida N; Kunishita Y; Kishimoto D; Kobayashi K; Kamiyama R; Yoshimi R; Kirino Y; Ohno S; Nakajima H
Int J Rheum Dis; 2019 Nov; 22(11):2009-2016. PubMed ID: 31515933
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study.
Yoshida K; Radner H; Mjaavatten MD; Greenberg JD; Kavanaugh A; Kishimoto M; Matsui K; Okada M; Reed G; Saeki Y; Tohma S; Kremer J; Solomon DH
J Rheumatol; 2015 Dec; 42(12):2238-46. PubMed ID: 26523025
[TBL] [Abstract][Full Text] [Related]
3. Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature.
Chen DY; Lau CS; Elzorkany B; Hsu PN; Praprotnik S; Vasilescu R; Marshall L; Llamado L
Int J Rheum Dis; 2018 Feb; 21(2):362-372. PubMed ID: 29205904
[TBL] [Abstract][Full Text] [Related]
4. Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry.
Yoshida K; Kishimoto M; Radner H; Matsui K; Okada M; Saeki Y; Solomon DH; Tohma S
Rheumatology (Oxford); 2016 Feb; 55(2):286-90. PubMed ID: 26350484
[TBL] [Abstract][Full Text] [Related]
5. Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.
Kalkan A; Husberg M; Hallert E; Roback K; Thyberg I; Skogh T; Carlsson P
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1679-85. PubMed ID: 26097219
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
[TBL] [Abstract][Full Text] [Related]
7. Treat-to-target and shared decision making in rheumatoid arthritis treatment: Is it feasible?
Falzer PR
Int J Rheum Dis; 2019 Sep; 22(9):1706-1713. PubMed ID: 31359630
[TBL] [Abstract][Full Text] [Related]
8. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan.
Tanaka E; Inoue E; Yamaguchi R; Shimizu Y; Kobayashi A; Sugimoto N; Hoshi D; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
Mod Rheumatol; 2017 Mar; 27(2):227-236. PubMed ID: 27472516
[TBL] [Abstract][Full Text] [Related]
10. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort.
Dierckx S; Sokolova T; Lauwerys BR; Avramovska A; de Bellefon LM; Toukap AN; Stoenoiu M; Houssiau FA; Durez P
Arthritis Res Ther; 2020 Apr; 22(1):96. PubMed ID: 32345367
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing.
Pontifex EK; Dissanayake K; Bursill D; Gill T
Int J Rheum Dis; 2019 Feb; 22(2):262-268. PubMed ID: 30450819
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study.
Jinno S; Onishi A; Dubreuil M; Akashi K; Hashimoto M; Yamamoto W; Murata K; Takeuchi T; Kotani T; Maeda Y; Ebina K; Son Y; Amuro H; Hara R; Katayama M; Saegusa J; Morinobu A
Rheumatol Int; 2020 Dec; 40(12):1987-1995. PubMed ID: 32728836
[TBL] [Abstract][Full Text] [Related]
13. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of down-titration versus continuation strategies of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis with low disease activity or in remission: a systematic review and meta-analysis.
Jiang M; Ren F; Zheng Y; Yan R; Huang W; Xia N; Luo L; Zhou J; Tang L
Clin Exp Rheumatol; 2017; 35(1):152-160. PubMed ID: 27749238
[TBL] [Abstract][Full Text] [Related]
15. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis.
Wilke T; Mueller S; Lee SC; Majer I; Heisen M
BMC Musculoskelet Disord; 2017 Aug; 18(1):332. PubMed ID: 28764705
[TBL] [Abstract][Full Text] [Related]
16. Relapse in rheumatoid arthritis patients undergoing dose reduction and withdrawal of biologics: are predictable factors more relevant than predictive parameters? An observational prospective real-life study.
Vittecoq O; Desouches S; Kozyreff M; Nicolau J; Pouplin S; Rottenberg P; Sens N; Lequerre T; Avenel G
BMJ Open; 2019 Dec; 9(12):e031467. PubMed ID: 31857303
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
18. Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study.
Gomez-Centeno A; Rubio-Romero E; Ovalles JG; Manrique-Arija S; Marsal-Barril S; Amarelo-Ramos J; Del Pino-Montes J; Muñoz-Fernández S; Bustabad S; Barbazán-Álvarez C
Rheumatol Int; 2019 Dec; 39(12):2015-2024. PubMed ID: 31396685
[TBL] [Abstract][Full Text] [Related]
19. Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry.
Hetland ML; Jensen DV; Krogh NS
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-141-6. PubMed ID: 25365104
[TBL] [Abstract][Full Text] [Related]
20. Dose down-titration of biological DMARDs in patients with rheumatoid arthritis over time and in daily clinical practice.
Rodriguez-Rodriguez L; Leon L; Lamas JR; Gomez A; Vadillo C; Blanco M; Jover JA; Abasolo L
Clin Exp Rheumatol; 2016; 34(5):872-879. PubMed ID: 27214094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]